Health and Healthcare
Gilead Sciences... The Beat Goes On (GILD)
Published:
Last Updated:
Gilead Sciences, Inc. (NASDAQ: GILD) posted results after the close today. Its Q1 revenues surged to $1.26 billion and non-GAAP earnings was $522.1 million, or $0.54 EPS. First Call had estimates at $0.48 EPS on $1.22 billion in revenues.
Gilead had cash and equivalents of $2.59 billion and generated $577.1 million of operating cash flows, which was offset by repurchases of $815.8 million of common stock. As of March 31, 2008, Gilead had approximately $2.15 billion remaining under this share repurchase program.
Its own product sales accounted for $1.14 Billion in Q1 revenues, up 36% because of a strong HIV franchise led by the continued strong uptake of Atripla.
Shares closed up 1.4% at $51.80 in normal trading, and shares rose 2.8% to $53.26 in after-hours trading. Its 52-week trading had been $35.22 to $53.20. Despite a 10-fold to 20-fold gain this decade, the company just keeps doing better and better.
Jon C. Ogg
April 16, 2008
Jon Ogg produces the Special Situation Investing Newsletter. He can be reached at [email protected] and he does not own securities in the companies he covers.
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.